Table 2.
Clinical characteristics of children with PEP due to VT v. NVT v. no pneumococcus
| Primary endpoint pneumonia (n = 176) | ||||
|---|---|---|---|---|
| Nasopharyngeal carriage | P value | |||
| No pneumococcus (n = 106) |
VT (n = 19) |
NVT (n = 51) |
||
|
Age in months, median (25th -75th IQR)a |
28 Months (16.9–36.2) |
22 Months (15.5–32.5) | 20 Months (15.2–28.4) | 0.16 |
| Prior antibiotic use (n = 70) | 44/106 (41.5%) | 7/19 (36.8%) | 19/51(37.2%) | 0.61 |
| Mother HIV positive (n = 26) | 16/106 (15.1%) | 4/19 (21.1%) | 6/51 (11.8%) | 0.31 |
| Child HIV positive (n = 13) | 8/106 (7,5%) | 2/19 (10.5%) | 3/51 (5.9%) | 0.64 |
| Fever (n = 125) | 79/106 (74.5%) | 12/19 (63.2%) | 34/51 (66.7%) | 0.43 |
| Cough (n = 175) | 105/106 (99.1%) | 19/19 (100%) | 51/51 (100%) | 1.00 |
| Apnoea (n = 3) | 3/106 (2.8%) | 0 (0%) | 0 (0%) | 0.68 |
| Nasal flaring (n = 155) | 94/106 (88.7%) | 17/19 (89.5%) | 44/51 (86.3%) | 0.94 |
| Chest indrawing (n = 152) | 92/106 (86.8%) | 16/19 (84.2%) | 44/51 (86.3%) | 0.95 |
| Stridor (n = 2) | 2/106 (1.9%) | 0 (0%) | 0 (0%) | 1.00 |
| Wheeze (n = 148) | 90/106 (84.9%) | 15/19 (78.9%) | 43/51 (84.3%) | 0.79 |
| Bronchial breathing (n = 96) | 57/106 (5.4%) | 11/19 (57.9%) | 28/51 (54.9%) | 0.97 |
| Reduced air entry (n = 106) | 47/106 (44.3%) | 10/19 (52.6%) | 18/51 (35.3%) | 0.38 |
IQR, interquartile range; HIV, human immunodeficiency virus; NVT, non-vaccine type; VT, vaccine type
aOne-way ANOVA